Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + famitinib malate
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Adebrelimab + famitinib malate is a combination therapy being developed by Jiangsu Hengrui Pharmaceuticals, often in collaboration with institutions like Anhui Provincial Cancer Hospital, for the treatment of advanced solid tumors including colorectal cancer. Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal antibody that targets programmed death-ligand 1 (PD-L1), preventing its binding to PD-1 and B7.1 receptors to enhance anti-tumor T-cell responses. Famitinib malate (SHR1020) is an orally bioavailable, multi-targeted small molecule tyrosine kinase inhibitor that primarily inhibits VEGFR2, PDGFR, and c-Kit, thereby suppressing tumor angiogenesis and cell proliferation. The combination aims to leverage the synergistic effects of immune checkpoint blockade and anti-angiogenic therapy to overcome resistance and improve clinical outcomes in patients with refractory malignancies.
- Other names
- adebrelimab + famitinib malateadbelimumab + famitinib malate
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)CD274 (Programmed cell death protein 1 ligand 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on adebrelimab + famitinib malate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + famitinib malate.